Cardax, Inc. Stock

CDXI

US14141D2018

Biotechnology & Medical Research

Market Closed - OTC Markets 14:59:54 2026-03-12 EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-

21-09-15	Cardax, Inc. announced a financing transaction	CI
21-08-31	Cardax, Inc. Announces Restructuring of Board of Directors	CI

Cardax, Inc. is a geroscience company focused on pharmaceutical and nutraceutical applications of astaxanthin. The Company markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. The Company is also advancing CDX-101, its pharmaceutical candidate, for the diseases of aging. CDX-101 is an astaxanthin Rx candidate for cardiovascular inflammation and dyslipidemia. CDX-301 is its zeaxanthin pharmaceutical candidate for macular degeneration. It may seek to monetize its CDX-301 pharmaceutical assets through licensing or sale.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Stock Market
Stocks
CDXI Stock

As early as today, start finding the best investment opportunities!

Market Cap	413K 354K 331K 303K 568K 39.5M 576K 3.91M 1.52M 19.84M 1.55M 1.52M 65.62M	P/E 2019	-1.36x	P/E 2020	-0.27x
Enterprise Value	5.17M 4.43M 4.15M 3.8M 7.13M 495M 7.22M 49M 19.11M 249M 19.43M 19.01M 823M	EV / Sales 2019	13,421,701x	EV / Sales 2020	11,249,008x
Free-Float	100%	Yield 2019 *	-	Yield 2020	-

21-09-15	Cardax, Inc. announced a financing transaction	CI
21-08-31	Cardax, Inc. Announces Restructuring of Board of Directors	CI
21-05-14	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-01-10	Cardax, Inc. announced that it expects to receive $10 million in funding from US Capital Global Investment Management, LLC	CI
20-11-17	Cardax, Inc. announced that it expects to receive $10 million in funding	CI
20-11-13	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-14	Cardax, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-05-15	Cardax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-03-30	Cardax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-03-15	Cardax, Inc. announced that it expects to receive $0.46 million in funding	CI
20-02-03	Cardax, Inc. has Changed its Ticker to CDXI from CDXID	CI
20-01-20	Cardax, Inc. announced that it expects to receive $0.25 million in funding from Harbor Gates Capital, LLC	CI
19-11-14	Cardax, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI

21-08-11	CARDAX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21-08-11	Cardax : Voluntarily Suspends SEC Reporting Obligations	PR
21-07-01	CARDAX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	AQ
21-05-14	CARDAX : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
21-05-14	Cardax : Reports Q1 2021 Results	PR

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		1.7
10 years	0		118

Manager	Title	Age	Since
David G. Watumull CEO	Chief Executive Officer	76	2014-02-06
David Watumull DFI	Director of Finance/CFO	44	2021-07-31
Gilbert Shin SAM	Sales & Marketing	-	2017-10-31

Cardax, Inc. Stock

Stocks

CDXI

US14141D2018

Biotechnology & Medical Research

Valuation: Cardax, Inc.

Chart: Cardax, Inc.

Latest news : Cardax, Inc.

Press Releases: Cardax, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cardax, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CARDAX, INC.	-99.00%	-.--%	-	-	0
LONZA GROUP AG	+1.09%	+3.39%	+3.50%	+25.49%	51.22B
REVOLUTION MEDICINES, INC.	-1.07%	+2.82%	+474.18%	+601.24%	45.38B
BEONE MEDICINES AG	+1.44%	+7.77%	+19.27%	+90.94%	41.97B
IQVIA HOLDINGS INC.	+1.47%	+9.79%	+40.15%	+21.21%	42.15B
CELLTRION, INC.	-0.93%	-4.80%	+17.39%	+46.60%	31.95B
ASCENDIS PHARMA A/S	-0.60%	+1.93%	-	-	16.73B
MEDPACE HOLDINGS, INC.	+1.32%	+7.30%	+36.93%	+152.36%	17.1B
EUROFINS SCIENTIFIC SE	+0.03%	+3.91%	+5.84%	+35.04%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	+5.41%	+91.01%	+46.93%	13.91B
Average	-9.50%	+2.87%	+86.03%	+127.48%	27.52B
Weighted average by Cap.	+0.46%	+3.13%	+103.46%	+149.23%

	2019	2020
Net sales	0.71 0.61 0.57 0.52 0.98 68.02 0.99 6.73 2.63 34.17 2.67 2.61 113.02	0.54 0.46 0.43 0.4 0.74 51.57 0.75 5.1 1.99 25.9 2.02 1.98 85.68
Net income	-5.09M -4.36M -4.08M -3.74M -7.01M -487M -7.11M -48.23M -18.81M -245M -19.12M -18.71M -810M	-5.06M -4.33M -4.05M -3.71M -6.96M -484M -7.05M -47.87M -18.67M -243M -18.98M -18.57M -804M
Net Debt	2.58M 2.21M 2.06M 1.89M 3.55M 246M 3.59M 24.39M 9.51M 124M 9.67M 9.46M 410M	4.76M 4.08M 3.82M 3.49M 6.56M 456M 6.64M 45.09M 17.58M 229M 17.88M 17.49M 757M